Showing results (71-80 of 681) with videos related to
Sort By:
Pageof 69
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2013
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistanceAlfonso Quintás-Cardama, Srdan VerstovsekCancer Chemotherapy and Pharmacology|March 28, 2016
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibJeffrey C Bryan, Srdan VerstovsekCurrent Hematologic Malignancy Reports|October 17, 2017
Prognostication and Initiation of Therapy in Polycythemia Vera: Do We Have it Right?Brady L Stein, Srdan VerstovsekCancer|April 6, 2022
The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomesJohn O Mascarenhas, Srdan VerstovsekCurrent Hematologic Malignancy Reports|August 6, 2022
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential ThrombocythemiaIvan Krecak, Marko Lucijanic, Srdan VerstovsekExpert Review of Hematology|April 1, 2023
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia veraIvan Krecak, Marko Skelin, Srdan VerstovsekClinical Lymphoma, Myeloma & Leukemia|November 1, 2011
JAK2 inhibitors: are they the solution?Fabio P S Santos, Srdan VerstovsekHematology/Oncology Clinics of North America|September 27, 2012
Therapy with JAK2 inhibitors for myeloproliferative neoplasmsFabio P S Santos, Srdan VerstovsekAnnals of Hematology|September 4, 2023
Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectivesIvan Krecak, Srdan Verstovsek, Marko LucijanicTherapeutics and Clinical Risk Management|March 9, 2012
Ruxolitinib for the treatment of myelofibrosis: its clinical potentialAlen Ostojic, Radovan Vrhovac, Srdan VerstovsekPageof 69